ReviewFrontiers in oncology2025
Advancements in research on the precise eradication of cancer cells through nanophotocatalytic technology.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid development of nanotechnology has significantly advanced the application of nanophotocatalysis in the medical field, particularly for cancer therapy. Traditional cancer treatments, such as chemotherapy and radiotherapy, often cause severe side effects, including damage to healthy tissues and the development of drug resistance. In contrast, nanophotocatalytic therapy offers a promising approach by utilizing nanomaterials that generate reactive oxygen species (ROS) under light activation, allowing for precise tumor targeting and minimizing collateral damage to surrounding tissues. This review systematically explores the latest advancements in highly efficient nanophotocatalysts for cancer treatment, focusing on their toxicological profiles, underlying mechanisms for cancer cell eradication, and potential for clinical application. Recent research shows that nanophotocatalysts, such as TiO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.